共 49 条
[1]
Buehlmayer P, Angiotensin II antagonists: Patent activity since the discovery of DuP‐753, Expert Opinion on Therapeutic Patents, 2, pp. 1693-1718, (1992)
[2]
Buehlmayer P, Furet P, Criscione L, Et al., Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series, Bioorganic & Medicinal Chemistry Letters, 4, pp. 29-34, (1994)
[3]
Carey R, Drake C, Dopamine selectively inhibits aldosterone responses to angiotensin II in humans, Hypertension, 8, pp. 399-406, (1986)
[4]
Chang RS, Siegl PK, Clineschmidt BV, Et al., In vitro pharmacology of L‐158,809, anew highly potent and selective angiotensin II receptor antagonist, J Pharmacol Exp Ther, 262, pp. 133-138, (1992)
[5]
Criscione L, de Gasparo M, Buehlmayer P, Whitebread S, Ramjoue HP, Wood JM, Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT1‐receptor subtype, Br J Pharmacol, 110, pp. 761-771, (1993)
[6]
de Gasparo M, Bottari S, Levens NR, Characteristics of angiotensin II receptors and their role in cell and organ physiology, Hypertension: Physiology, Diagnosis, and Management, pp. 1695-1720, (1994)
[7]
de Gasparo M, Husain A, Alexander W, Et al., A proposed update of the nomenclature of angiotensin receptors, Hypertension, 25, pp. 924-927, (1995)
[8]
de Gasparo M, Levens NR, Kamber B, Et al., The angiotensin II AT2 receptor subtype, Angiotensin Receptor, pp. 95-117, (1993)
[9]
de Gasparo M, Whitebread S, Binding of valsartan to mammalian AT1 receptors, Regul Pept, 59, pp. 303-311, (1995)
[10]
de Gasparo M, Whitebread S, Levens N, Et al., Pharmacology of angiotensin II receptor subtypes, Cellular and Molecular Biology of the Adrenal Cortex. (Colloque INSERM, Vol 222), pp. 3-17, (1992)